Claim OwnershipThe TBPod
Subscribed: 19Played: 256
Subscribe
© 2025 The TBPod
Description
The TBPod is a podcast for clinicians and policymakers caring for patients with tuberculosis. The podcasts present discussions with expert clinicians, researchers, policymakers and advocates about their work in the field of tuberculosis. Tuberculosis remains one of the leading causes of death worldwide, and is an important contributor to morbidity among migrants arriving in Australia and New Zealand. There are around 1300 reported cases of TB in Australia each year, and a further 300 in New Zealand. Included in these figures are cases of multi-drug resistant (MDR) TB which pose significant barriers to treatment and management of the disease. The Australian government has committed to the global elimination of TB by 2030, but to do so requires the development of innovative new strategies, based on high-quality research, that has national and international reach. These podcasts aim to engage and update those who are interested in the field of tuberculosis through discussions with leaders in the field of tuberculosis.
46 Episodes
Reverse
Dr Joseph Donovan, clinical researcher at OUCRU Vietnam and Associate Research Fellow at the University of Oxford, joins Dr Angus Lane, medical registrar to discuss the global burden and diagnostic challenges of tuberculosis meningitis (TBM). He outlines key findings from major trials in Vietnam and Indonesia, including the ACT HIV trial of adjunctive dexamethasone, discusses global practice guidelines, and highlights existing and emerging evidence on antiretroviral timing, aspirin, and rifam...
Catherine Berry, ACTnet Steering Committee member and ID physician at John Hunter Hospital, Newcastle, was joined by Dr Jodie Schildkraut and Dr Van Le Hong, key researchers in the global Unite4TB consortium, which is accelerating the development of new TB treatments. Dr Schildkraut, based at Radboud University Medical Center, leads the Phase 2B/C clinical trials work package and coordinates across multiple TB consortia. Dr Van Le Hong, a pulmonologist and clinical research fellow at OUCRU Vi...
Associate Professor Nicolas Alan Menzies, from the School of Global Health and Population at the Harvard T.H. Chan School of Public Health in Boston, Massachusetts, joins Dr Andrew Burke to discuss his research on the contribution of post-TB sequelae to life-years and quality-adjusted life-years lost due to TB disease in the United States. Drawing on data from both U.S. and Brazilian cohorts, he explores how a significant portion of TB’s health burden, including elevated mortality and reduced...
Dr Matthew Burman is a TB clinician and researcher from East London, Queen Mary University and the Blizzard Institute. Today he presents the data from the CATAPULT trial which randomised patients to either have their latent TB infection managed by a TB clinic in secondary care, or be managed in primary care by their GP in concert with a community pharmacist. This amazing trial re-evaluates how we think about TB preventative therapy and looks at new ways of approaching the burden of latent TB ...
Dr. Stijn Deborggraeve is the Diagnostics Advisor Infectious Diseases at Médecins Sans Frontières (MSF) Access Campaign. In this episode we discussed GeneXpert technology including pricing, logistics, and future developments.
Dr Graeme Hoddinott is a Senior Lecturer in Global Health at the University of Sydney. He is also an Extraordinary Associate Professor in paediatrics at Stellenbosch University. Much of his research experience is on tuberculosis, especially among children, adolescents, and their families. In this episode, we explore ground-breaking research on the preferences of children and adolescents in tuberculosis (TB) treatment and management, revealing surprising insights that could lead to bet...
Associate Professor Sarah Bernays, co-director of the Masters of Global Health program at the University of Sydney, leads a social science research program focused on community engagement in infectious disease prevention, treatment, and care. Her work emphasizes understanding how individuals, households, and communities respond to health adversity, risk, and vulnerability while fostering resilience and hope. In this episode, we explored the perspectives of tuberculosis patients, the challen...
Professor Guy Marks AO FAHMS is a distinguished respiratory and public health physician and environmental epidemiologist. Currently serving as the President and interim Executive Director of the International Union Against Tuberculosis and Lung Disease (The Union), he has led the Respiratory and Environmental Epidemiology group at the Woolcock Institute since 1997. His research primarily focuses on lung health, with particular emphasis on airway diseases, air pollution, and tuberculosis. Addi...
Amanda Christensen joins us in this month's edition to discuss the critical impact of nurses in the fight against tuberculosis. Amanda is the Executive Director at the Australian Respiratory Council and is deeply experienced in the field of tuberculosis care. We explored the ideal attributes of TB nurses, offering perspectives on tuberculosis both within Australia and across the Pacific. We discussed the importance of patient advocacy, examined the structure and management of TB programs wit...
Today we had the pleasure of being joined by Associate Professor Patrick Phillips from the University of California, who is the Co-Director of the UC Tuberculosis Research Advancement Center, Clinical & Population Health Science Core. Patrick has a wealth of statistical experience and specialises in the design, implementation, and optimisation of clinical trials for new treatments for drug-sensitive and drug-resistant tuberculosis. Join us as we explore the rapidly evolving field of TB c...
Handaa Enkh Amgalan is an author, TB advocate and director of QA at the International Rescue Committee in Germany who has not only recently spoken at the UN TB High Level Meeting but also written an incredible memoir of her experience being diagnosed with severe pulmonary tuberculosis as a teenager growing up in Mongolia. Handaa gives an incredible insight into what it means to be diagnosed with such a stigmatising disease as a young woman; how it affect her, her family, and her dreams. This ...
Professor Adrian Martineau from the Queen Mary University London talks to us about the limitations of current latent TB infection diagnosis and how we can do better. his research into whether we can use fragments of TB DNA found in bone marrow cells to better predict who should be treated with Tuberculosis Preventative Treatment. REFERENCES Martineau, Adrian R., et al. "Towards a molecular microbial blood test for tuberculosis infection." International Journal of Infectious Diseases (2...
Today we discuss the MTBVAC with Dr Montañés. MTBVAC is an attenuated vaccine from a human mycobacterial isolate which has just progressed to a phase 3 trial and shown very promising results in the phase 2 study. Dr Montañés has been involved in this project for over a decade and has an incredible insight into the development and promise of this vaccine for global TB epidemiology. References Martín, Carlos, et al. "MTBVAC, a live TB vaccine poised to initiate efficacy trials 100 years after ...
Prof Greg Fox speaks with Prof Philip Hill about TB household contact tracing and building research capacity in TB. Prof Hill is an ID specialist and public health physician who did his PhD in TB Epidemiology. He is the current McAuley Chair in International Health as well as being Founding Direction & Co-Director of the Centre for International Health at the University of Otago. References 1) Martinez, Leonardo, et al. "The risk of tuberculosis in children after close exposure: a syst...
Today we speak with Dr Guglielmetti about the END-TB trial which looks at new all oral regimens for MDR-TB. REFERENCES 1) https://endtb.org/ 2) Nyang’wa, Bern-Thomas, et al. "A 24-week, all-oral regimen for rifampin-resistant tuberculosis." New England Journal of Medicine 387.25 (2022): 2331-2343. 3) Conradie, Francesca, et al. "Treatment of highly drug-resistant pulmonary tuberculosis." New England Journal of Medicine 382.10 (2020): 893-902. 4) Diacon, Andreas H., et al. "Multidrug-resistan...
Today we delve into the world of TB diagnostics and the future of leveraged TB technologies with Dr Morten Ruhwald. Dr Ruhwald is a the head of the TB programme over at FIND, an institution dedicated to accelerating equitable access to reliable diagnosis around the world. Dr Ruhwald elaborates on the current state of TB diagnostics, new clinical strategies, usability factors, and future TB perspectives. https://www.finddx.org/what-we-do/programmes/tuberculosis/ https://www.actnet.org....
Today we speak with Dr Chris Lowbridge about the amazing work of the TB teams in the Northern Territory. Chris talks about the challenges of controlling tuberculosis across 1.42 million square kilometres, more than 100 local languages, and some very isolated communities. References Meumann, Ella M., et al. "Tuberculosis in Australia's tropical north: a population-based genomic epidemiological study." The Lancet Regional Health–Western Pacific 15 (2021). Vigneswaran, Nilanthy, et al. "Factor...
Today we speak with Dr Clifton Barry from NIH in Bethesda, Maryland who is head of the most highly cited research group in the field of TB over the past year and has made extraordinary contributions to TB drug development. Dr Barry speaks about his involvement in the PREDICT TB study, the TB Drug Accelerator and some of the most exciting drug developments in recent years. REFERENCES Green, Simon R., et al. "Lysyl-tRNA synthetase, a target for urgently needed M. tuberculosis drugs." Nature co...
Today we get an update on where the TB Vaccine pipeline is up to, how TB vaccines work and what exciting candidates might be on the horizon. We speak with Professor Jamie Triccas from the University of Sydney about his work as the principal investigator on the Advancing Vaccine Adjuvant Research for Tuberculosis (AVAR-T) which is an NIH funded project to identify the most promising adjuvant-TB immunogenicity candidates for development. REFERENCES Stewart, Erica, James A. Triccas, and Nikolai...
Today we have the pleasure of speaking with Professor Giovanni Migliori about TB Elimination. Professor Migliori is the director of the WHO collaborating centre for TB and lung disease and is the current chief editor for the international journal of TB and lung disease. He was formerly the secretary general of the ERS and president of the Union's European region. Today he speaks about his recent viewpoint publication regarding how different countries should be approaching TB control and elimi...
Comments
Download from Google Play
Download from App Store
United States